Verdiva Bio

Our Chairman, Mark Pruzanski, MA, MD, previously Chairman and CEO of Versanis Bio and founder and CEO of Intercept Pharmaceuticals, commented on the substantial Series A financing, co-led by Forbion and General Atlantic, saying: “This significant Series A financing will be used to progress the clinical development of our existing assets as well as to expand our industry-leading cardiometabolic portfolio, and we are grateful to this top-tier investor syndicate for their support”. See more in our news release here: www.verdivabio.com/news #launch #cardiometabolic #obesity #innovation

CEO, Khurem Farooq, formerly CEO of Aiolos Bio and Gyroscope Therapeutics, will lead our experienced team of drug developers and biotech company builders. On the launch today, he commented: “People living with obesity and its complications deserve better options at each stage of their treatment journey, including oral therapies with less frequent dosing regimens, the potential for improved efficacy and tolerability, and innovative combination therapies in pursuit of healthier weight loss and, equally importantly, maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs”. “Our most mature program has the potential to be a first-in-class, once-weekly oral treatment for obesity and weight loss maintenance that could dramatically improve patient access and affordability.” See more in our news release here: https://lnkd.in/ebpzKqxX #launch #cardiometabolic #obesity #innovation

We’re proud to introduce Verdiva Bio! Launching today, a new clinical-stage cardiometabolic company, with $411m funding to advance next-generation therapies. 💡 Developing a broad portfolio of oral and injectable treatments with best-in-class potential to treat obesity, cardiometabolic disorders, and related complications 💡  Groundbreaking potential of our once-weekly oral GLP-1 and oral amylin therapies for the treatment of obesity including weight loss and maintenance 💡  Differentiated and clinically validated proprietary oral delivery technology focused on patient-friendly dosing, greater scalability, and broader patient access. 💡  Proven team of experienced drug developers and company builders, led by CEO Khurem Farooq and Chair Mark Pruzanski, MA, MD with Mohamed Eid, MD, MSc, MHA as CMO, formerly of Boehringer Ingelheim and Novo Nordisk. 💡  Oversubscribed $411m Series A financing with A-grade investor syndicate – led by Forbion, and General Atlantic along with RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures 礼来亚洲基金 and LYFE Capital See more in our news release here: https://lnkd.in/ebpzKqxX #launch #cardiometabolic #obesity #innovation